Premium
Enhanced immunity and antiviral effects of an HBV DNA vaccine delivered by a DC ‐targeting protein
Author(s) -
Wang Y.,
Wu S.,
Wang Z. C.,
Zhu X. M.,
Yin X. T.,
Gao K.,
Du Z. Y.,
Chen G. Z.,
Yu J. Y.
Publication year - 2016
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/jvh.12542
Subject(s) - virology , immunity , dna vaccination , dna , biology , medicine , immune system , immunology , genetics , plasmid
Summary DNA vaccine targeting delivery to DC represents one effective strategy to improve the immunogenicity of the vaccine. In a previous study, we developed a novel DC ‐targeting recombinant protein that can deliver plasmid DNA to DC s by an electrostatic coupling effect and can thus improve the uptake efficiency of DC s, improving the expression of plasmid DNA in DC s. In this study, we coupled the protein with the HBV DNA vaccine pSVK ‐ HBVA and investigated whether the immunogenicity and antiviral ability of the vaccine can be improved in HBV transgenic mice. The results show that a stronger specific immune response can be induced in mice after immunization with the coupling vaccine. The HBV DNA copy number and circulating antigen HB sAg in the serum of HBV transgenic mice were significantly decreased. Therefore, this study has demonstrated that the DC ‐targeting protein has the ability to improve the immunogenicity and the antiviral activity of the HBV DNA vaccine pSVK ‐ HBVA . These findings indicate that this DC ‐targeting protein can be a potential method for the delivery of DNA vaccines directly to DC s.